Use ImmunoSeq Online
Commercially Available ImmunoSeq No-Code Web Server
ImmunoSeq: A New Tool for Therapeutic Antibody Design and Optimization
Therapeutic antibody development faces a persistent and critical bottleneck: immunogenicity caused by the induction of anti-drug antibodies (ADA). ADA can neutralize drug activity, diminish clinical efficacy, or trigger life-threatening adverse reactions such as cytokine release syndrome. Identifying short peptide fragments presented by the major histocompatibility complex (MHC)—the T cell epitopes that drive ADA formation—is the central challenge in prediction.
ImmunoSeq provides an interpretable, applicable, and mechanism-driven computational framework rooted in the biological principles of immune tolerance. By shifting away from opaque, "black-box" deep learning alternatives, ImmunoSeq evaluates sequence humanness with residue-level resolution, allowing researchers to accurately spot immunogenic hotspots and precisely optimize candidate sequences.
How ImmunoSeq Works
ImmunoSeq utilizes a unique dual-library peptide matching approach that mirrors the human immune system’s capability to discriminate between self and non-self proteins.
Dual-Library Architecture: ImmunoSeq establishes a virtual repository composed of two distinct libraries:
Positive Self-Peptide Library: Contains over 700 million immunologically safe peptides derived from systematically fragmenting >21,000 unique human proteome sequences and >1.1 million healthy human paired antibody sequences from the Observed Antibody Space (OAS) dataset.
Negative Non-Self-Peptide Library: Contains over 40 million peptides derived from >84,000 paired mouse antibody sequences, capturing evolutionary-selected immunogenic triggers.
MHC-Relevant Fragmentation: Input antibody sequences are fragmented into overlapping k-mer peptides (k = 8-12 amino acids). This precisely covers the major cleft binding dimensions of MHC Class I (8-10) and Class II (10-12) molecules to capture critical T cell receptor engagement zones.
The Hit Rate Metric: Input fragments are evaluated against both libraries. Each positive library match yields a score of +1.0, while negative library matches receive a -0.2 penalty to balance the disparity in library sizes. The global hit rate averages these scores across the heavy and light chains, returning a normalized metric between -0.2 (high immunogenicity risk) and +1.0 (high tolerance). Higher hit rates reliably predict lower clinical ADA risk.
Residue-Level Resolution: By calculating local hit rates across all fragments containing a specific residue, ImmunoSeq flags individual amino acids with low scores as potential immunogenic hotspots, providing transparent and highly actionable structural guidance.
What is Tamarind Bio?
Tamarind Bio is a pioneering no-code bioinformatics platform built to democratize access to powerful computational tools for life scientists and researchers. Recognizing that many cutting-edge machine learning models are often difficult to deploy and use, Tamarind provides an intuitive, web-based environment that completely abstracts away the complexities of high-performance computing, software dependencies, and command-line interfaces.
The platform is designed to provide easy access to biologists, chemists, and other researchers who may not have a background in programming or cloud infrastructure but want to run experimental models with their data. Key features include a user-friendly graphical interface for setting up and launching experiments, a robust API for integration into existing research pipelines, and an automated system for managing and scaling computational resources. By handling the technical heavy lifting, Tamarind empowers researchers to concentrate on their scientific questions and accelerate the pace of discovery. The Tamarind team holds information/data security as a top priority, as detailed in our Trust Center & Terms of Service, ensuring your data is safe on the platform.
Accelerating Discovery with ImmunoSeq on Tamarind Bio
Deploying ImmunoSeq on Tamarind Bio accelerates the design of safe, highly efficacious biotherapeutics through seamless workflows:
State-of-the-Art Benchmarking: ImmunoSeq demonstrates superior clinical ADA risk correlation (R = -0.53) and humanness classification accuracy (ROC-AUC of 0.982, MCC of 0.910), outperforming established deep learning and machine learning sequence models like AbNatiV, Hu-mAb, and OASis.
Precision Sequence Humanization: Validated across 25 historical humanization cases, ImmunoSeq successfully tracks and drives sequence optimization. Its top-ranked recommendations correlate heavily with experimentally proven beneficial mutations.
Support for Diverse Modalities: Beyond standard IgG conventional antibodies, ImmunoSeq safely evaluates non-canonical antibody architectures, such as single-domain nanobodies.
Multi-Parameter Engineering Funnel: On Tamarind Bio, clinicians can generate high-scoring ImmunoSeq sequence mutations and seamlessly funnel them into downstream tools (like Rosetta or AlphaFold3) to concurrently evaluate binding affinity, thermostability, and aggregation propensity.
How to Use ImmunoSeq on Tamarind Bio
To leverage the interpretive power of ImmunoSeq on Tamarind Bio, follow this straightforward, no-code workflow:
Access the Platform: Log in to your account at app.tamarind.bio.
Select ImmunoSeq: Choose the ImmunoSeq tool from the available catalog of antibody design and optimization models.
Input Candidate Sequences: Upload or paste the amino acid sequences of your candidate antibody's variable regions (Heavy and Light chains, or Single-Domain formats).
Analyze Baseline Hit Rate: Run a baseline evaluation to visualize your global hit rate score alongside a residue-by-residue local profile chart to instantly locate problematic immunogenic hotspots.
Choose an Optimization Strategy: Select how you want to design lower-risk mutations:
One-Shot Design: Instantly enumerate and rank all single-point framework region mutations by their immediate capability to boost your hit rate.
Greedy Iterative Design: Allow the web server to run stepwise cycles, automatically picking and incorporating the absolute top-performing mutations until your sequence safely plateaus at a high tolerance trajectory (converging around a mean hit rate of 0.84).
Evaluate and Export: Review recommended mutations that cleanly mitigate surface immunogenicity while automatically preserving framework stability. Export the optimized sequence variants directly for absolute wet-lab synthesis and experimental screening.